High expression of stratifin is a universal abnormality during the course of malignant progression of early-stage lung adenocarcinoma

International Journal of Cancer

Volumn 129, Issue 10, 2011, Pages 2445-2453

  Shiba Ishii, Aya ^a   Kano, Junko ^a   Morishita, Yukio ^a   Sato, Yukio ^a   Minami, Yuko ^a   Noguchi, Masayuki ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

adenocarcinoma; lung cancer; stratifin; tumor promotion and progression

Indexed keywords

COMPLEMENTARY DNA; RNA; SMALL INTERFERING RNA; STRATIFIN;

ARTICLE; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE COURSE; DNA MICROARRAY; EARLY CANCER; ENZYME IMMUNOASSAY; FATALITY; GENE AMPLIFICATION; GENE EXPRESSION; GENETIC SELECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LYMPH NODE METASTASIS; MALIGNANT TRANSFORMATION; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BINDING; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

14-3-3 PROTEINS; ADENOCARCINOMA; ANIMALS; CELL LINE, TUMOR; DISEASE PROGRESSION; EXONUCLEASES; LUNG NEOPLASMS; LYMPHATIC METASTASIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 80955180970     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25907     Document Type: Article

References (37)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-49.
2. Noguchi M, Morikawa A, Kawasaki M, Matsuno Y, Yamada T, Hirohashi S, Kondo H, Shimosato Y,. Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer 1995; 75: 2844-52.
3. Suzuki K, Yokose T, Yoshida J, Nishimura M, Takahashi K, Nagai K, Nishiwaki Y,. Prognostic significance of the size of central fibrosis in peripheral adenocarcinoma of the lung. Ann Thorac Surg 2000; 69: 893-7. (Pubitemid 30184718)
4. Sakurai H, Maeshima A, Watanabe S, Suzuki K, Tsuchiya R, Maeshima AM, Matsuno Y, Asamura H,. Grade of stromal invasion in small adenocarcinoma of the lung: histopathological minimal invasion and prognosis. Am J Surg Pathol 2004; 28: 198-206. (Pubitemid 38124728)
5. Shimada A, Kano J, Ishiyama T, Okubo C, Iijima T, Morishita Y, Minami Y, Inadome Y, Shu Y, Sugita S, Takeuchi T, Noguchi M,. Establishment of an immortalized cell line from a precancerous lesion of lung adenocarcinoma, and genes highly expressed in the early stages of lung adenocarcinoma development. Cancer Sci 2005; 96: 668-75. (Pubitemid 41723543)
6. Aoyagi K, Tatsuta T, Nishigaki M, Akimoto S, Tanabe C, Omoto Y, Hayashi S, Sakamoto H, Sakamoto M, Yoshida T, Terada M, Sasaki H,. A faithful method for PCR-mediated global mRNA amplification and its integration into microarray analysis on laser-captured cells. Biochem Biophys Res Commun 2003; 300: 915-20. (Pubitemid 36259849)
7. Esme H, Cemek M, Sezer M, Saglam H, Demir A, Melek H, Unlu M,. High levels of oxidative stress in patients with advanced lung cancer. Respirology 2008; 13: 112-6.
8. Perathoner A, Pirkebner D, Brandacher G, Spizzo G, Stadlmann S, Obrist P, Margreiter R, Amberger A,. 14-3-3sigma expression is an independent prognostic parameter for poor survival in colorectal carcinoma patients. Clin Cancer Res 2005; 11: 3274-9. (Pubitemid 40627875)
9. Zhang Y, Karas M, Zhao H, Yakar S, LeRoith D,. 14-3-3sigma mediation of cell cycle progression is p53-independent in response to insulin-like growth factor-I receptor activation. J Biol Chem 2004; 279: 34353-60. (Pubitemid 39318060)
10. Dougherty MK, Morrison DK,. Unlocking the code of 14-3-3. J Cell Sci 2004; 117: 1875-84. (Pubitemid 38745122)
11. Fu H, Subramanian RR, Masters SC,. 14-3-3 proteins: structure, function, and regulation. Annu Rev Pharmacol Toxicol 2000; 40: 617-47. (Pubitemid 30340695)
12. Hermeking H,. The 14-3-3 cancer connection. Nat Rev Cancer 2003; 3: 931-43. (Pubitemid 37500178)
13. Hermeking H, Lengauer C, Polyak K, He TC, Zhang L, Thiagalingam S, Kinzler KW, Vogelstein B,. 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell 1997; 1: 3-11. (Pubitemid 127376388)
14. Chan TA, Hermeking H, Lengauer C, Kinzler KW, Vogelstein B,. 14-3-3Sigma is required to prevent mitotic catastrophe after DNA damage. Nature 1999; 401: 616-20.
15. Laronga C, Yang HY, Neal C, Lee MH,. Association of the cyclin-dependent kinases and 14-3-3 sigma negatively regulates cell cycle progression. J Biol Chem 2000; 275: 23106-12. (Pubitemid 30646202)
16. Dellambra E, Golisano O, Bondanza S, Siviero E, Lacal P, Molinari M, D'Atri S, De Luca M,. Downregulation of 14-3-3sigma prevents clonal evolution and leads to immortalization of primary human keratinocytes. J Cell Biol 2000; 149: 1117-30.
17. Umbricht CB, Evron E, Gabrielson E, Ferguson A, Marks J, Sukumar S,. Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer. Oncogene 2001; 20: 3348-53. (Pubitemid 32588983)
18. Ferguson AT, Evron E, Umbricht CB, Pandita TK, Chan TA, Hermeking H, Marks JR, Lambers AR, Futreal PA, Stampfer MR, Sukumar S,. High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer. Proc Natl Acad Sci USA 2000; 97: 6049-54. (Pubitemid 30367521)
19. Gasco M, Bell AK, Heath V, Sullivan A, Smith P, Hiller L, Yulug I, Numico G, Merlano M, Farrell PJ, Tavassoli M, Gusterson B, et al. Epigenetic inactivation of 14-3-3 sigma in oral carcinoma: association with p16(INK4a) silencing and human papillomavirus negativity. Cancer Res 2002; 62: 2072-6. (Pubitemid 34408454)
20. Iwata N, Yamamoto H, Sasaki S, Itoh F, Suzuki H, Kikuchi T, Kaneto H, Iku S, Ozeki I, Karino Y, Satoh T, Toyota J, et al. Frequent hypermethylation of CpG islands and loss of expression of the 14-3-3 sigma gene in human hepatocellular carcinoma. Oncogene 2000; 19: 5298-302.
21. Lodygin D, Diebold J, Hermeking H,. Prostate cancer is characterized by epigenetic silencing of 14-3-3sigma expression. Oncogene 2004; 23: 9034-41. (Pubitemid 40013070)
22. Suzuki H, Itoh F, Toyota M, Kikuchi T, Kakiuchi H, Imai K,. Inactivation of the 14-3-3 sigma gene is associated with 5′ CpG island hypermethylation in human cancers. Cancer Res 2000; 60: 4353-7. (Pubitemid 32103610)
23. Urano T, Saito T, Tsukui T, Fujita M, Hosoi T, Muramatsu M, Ouchi Y, Inoue S,. Efp targets 14-3-3 sigma for proteolysis and promotes breast tumour growth. Nature 2002; 417: 871-5.
24. Nakanishi K, Hashizume S, Kato M, Honjoh T, Setoguchi Y, Yasumoto K,. Elevated expression levels of the 14-3-3 family of proteins in lung cancer tissues. Hum Antibodies 1997; 8: 189-94. (Pubitemid 27501222)
25. Moreira JM, Ohlsson G, Rank FE, Celis JE,. Down-regulation of the tumor suppressor protein 14-3-3sigma is a sporadic event in cancer of the breast. Mol Cell Proteomics 2005; 4: 555-69. (Pubitemid 40590572)
26. Osada H, Tatematsu Y, Yatabe Y, Nakagawa T, Konishi H, Harano T, Tezel E, Takada M, Takahashi T,. Frequent and histological type-specific inactivation of 14-3-3sigma in human lung cancers. Oncogene 2002; 21: 2418-24. (Pubitemid 34407301)
27. Villaret DB, Wang T, Dillon D, Xu J, Sivam D, Cheever MA, Reed SG,. Identification of genes overexpressed in head and neck squamous cell carcinoma using a combination of complementary DNA subtraction and microarray analysis. Laryngoscope 2000; 110: 374-81. (Pubitemid 30143678)
28. Shimomura K, Sakakura C, Fujita Y, Nakanishi M, Hagiwara A, Yamagishi H,. [Overexpression of 14-3-3 in primary gastric cancers and clinical application for the detection of micrometastases in the peritoneal cavity]. Nippon Geka Gakkai Zasshi 2002; 103: 386.
29. Friess H, Ding J, Kleeff J, Fenkell L, Rosinski JA, Guweidhi A, Reidhaar-Olson JF, Korc M, Hammer J, Buchler MW,. Microarray-based identification of differentially expressed growth- and metastasis-associated genes in pancreatic cancer. Cell Mol Life Sci 2003; 60: 1180-99. (Pubitemid 36791920)
30. Iacobuzio-Donahue CA, Ashfaq R, Maitra A, Adsay NV, Shen-Ong GL, Berg K, Hollingsworth MA, Cameron JL, Yeo CJ, Kern SE, Goggins M, Hruban RH,. Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res 2003; 63: 8614-22. (Pubitemid 38064035)
31. Logsdon CD, Simeone DM, Binkley C, Arumugam T, Greenson JK, Giordano TJ, Misek DE, Kuick R, Hanash S,. Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res 2003; 63: 2649-57. (Pubitemid 36605209)
32. Ide M, Nakajima T, Asao T, Kuwano H,. Inactivation of 14-3-3sigma by hypermethylation is a rare event in colorectal cancers and its expression may correlate with cell cycle maintenance at the invasion front. Cancer Lett 2004; 207: 241-9. (Pubitemid 38457046)
33. Yoeli-Lerner M, Toker A,. Akt/PKB signaling in cancer: a function in cell motility and invasion. Cell Cycle 2006; 5: 603-5.
34. Cantley LC,. The phosphoinositide 3-kinase pathway. Science 2002; 296: 1655-7. (Pubitemid 34579158)
35. Hanahan D, Weinberg RA,. The hallmarks of cancer. Cell 2000; 100: 57-70. (Pubitemid 30046295)
36. Bouwknecht JA, Paylor R,. Behavioral and physiological mouse assays for anxiety: a survey in nine mouse strains. Behav Brain Res 2002; 136: 489-501. (Pubitemid 35333265)
37. Chen CH, Lai JM, Chou TY, Chen CY, Su LJ, Lee YC, Cheng TS, Hong YR, Chou CK, Whang-Peng J, Wu YC, Huang CY,. VEGFA upregulates FLJ10540 and modulates migration and invasion of lung cancer via PI3K/AKT pathway. PLoS One 2009; 4: e5052.